Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07468552 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 14 words Secondary endpoints: details revised at 2 of 6 entries Show 1 more changeShow less
    • Secondary endpoints: details revised at 2 of 6 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
Trial Details
NCT Number NCT07468552
Lead Sponsor National Institute on Drug Abuse (NIDA)
Conditions Cannabis Use Disorder
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov